Amsbio is helping researchers fast-track CAR-T cell therapy development with a growing portfolio of experimental cell lines, ...

DNA segments that are naturally excised during immune-cell development can replicate, drive damage at various genomic sites and lead to cancer recurrence. Karla K. Rodgers is in the Department of ...

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid ...

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in ...

Armed with $120 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager (TCE) space. Ouro Medicines launched Friday with the goal of harnessing T ...

The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...